Literature DB >> 26194311

The Alzheimer's Disease Neuroimaging Initiative 2 PET Core: 2015.

William J Jagust1, Susan M Landau2, Robert A Koeppe3, Eric M Reiman4, Kewei Chen4, Chester A Mathis5, Julie C Price5, Norman L Foster6, Angela Y Wang6.   

Abstract

INTRODUCTION: This article reviews the work done in the Alzheimer's Disease Neuroimaging Initiative positron emission tomography (ADNI PET) core over the past 5 years, largely concerning techniques, methods, and results related to amyloid imaging in ADNI.
METHODS: The PET Core has used [(18)F]florbetapir routinely on ADNI participants, with over 1600 scans available for download. Four different laboratories are involved in data analysis, and have examined factors such as longitudinal florbetapir analysis, use of [(18)F]fluorodeoxyglucose (FDG)-PET in clinical trials, and relationships between different biomarkers and cognition.
RESULTS: Converging evidence from the PET Core has indicated that cross-sectional and longitudinal florbetapir analyses require different reference regions. Studies have also examined the relationship between florbetapir data obtained immediately after injection, which reflects perfusion, and FDG-PET results. Finally, standardization has included the translation of florbetapir PET data to a centiloid scale.
CONCLUSION: The PET Core has demonstrated a variety of methods for the standardization of biomarkers such as florbetapir PET in a multicenter setting.
Copyright © 2015 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alzheimer's disease; Amyloid; Fluorodeoxyglucose; Mild cognitive impairment; PET imaging

Mesh:

Substances:

Year:  2015        PMID: 26194311      PMCID: PMC4510459          DOI: 10.1016/j.jalz.2015.05.001

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   21.566


  48 in total

1.  Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET.

Authors:  Nobuyuki Okamura; Shozo Furumoto; Michelle T Fodero-Tavoletti; Rachel S Mulligan; Ryuichi Harada; Paul Yates; Svetlana Pejoska; Yukitsuka Kudo; Colin L Masters; Kazuhiko Yanai; Christopher C Rowe; Victor L Villemagne
Journal:  Brain       Date:  2014-03-27       Impact factor: 13.501

2.  Longitudinal change of biomarkers in cognitive decline.

Authors:  Raymond Y Lo; Alan E Hubbard; Leslie M Shaw; John Q Trojanowski; Ronald C Petersen; Paul S Aisen; Michael W Weiner; William J Jagust
Journal:  Arch Neurol       Date:  2011-06-13

3.  Amyloid-β imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods.

Authors:  Susan M Landau; Christopher Breault; Abhinay D Joshi; Michael Pontecorvo; Chester A Mathis; William J Jagust; Mark A Mintun
Journal:  J Nucl Med       Date:  2012-11-19       Impact factor: 10.057

4.  Vascular burden and Alzheimer disease pathologic progression.

Authors:  Raymond Y Lo; William J Jagust
Journal:  Neurology       Date:  2012-09-12       Impact factor: 9.910

5.  Summary metrics to assess Alzheimer disease-related hypometabolic pattern with 18F-FDG PET: head-to-head comparison.

Authors:  Anna Caroli; Annapaola Prestia; Kewei Chen; Napatkamon Ayutyanont; Susan M Landau; Cindee M Madison; Cathleen Haense; Karl Herholz; Flavio Nobili; Eric M Reiman; William J Jagust; Giovanni B Frisoni
Journal:  J Nucl Med       Date:  2012-02-17       Impact factor: 10.057

6.  Comparison of 11C-PiB and 18F-florbetaben for Aβ imaging in ageing and Alzheimer's disease.

Authors:  Victor L Villemagne; Rachel S Mulligan; Svetlana Pejoska; Kevin Ong; Gareth Jones; Graeme O'Keefe; J Gordon Chan; Kenneth Young; Henri Tochon-Danguy; Colin L Masters; Christopher C Rowe
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-03-08       Impact factor: 9.236

7.  The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET.

Authors:  William E Klunk; Robert A Koeppe; Julie C Price; Tammie L Benzinger; Michael D Devous; William J Jagust; Keith A Johnson; Chester A Mathis; Davneet Minhas; Michael J Pontecorvo; Christopher C Rowe; Daniel M Skovronsky; Mark A Mintun
Journal:  Alzheimers Dement       Date:  2014-10-28       Impact factor: 21.566

8.  Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study.

Authors:  Victor L Villemagne; Samantha Burnham; Pierrick Bourgeat; Belinda Brown; Kathryn A Ellis; Olivier Salvado; Cassandra Szoeke; S Lance Macaulay; Ralph Martins; Paul Maruff; David Ames; Christopher C Rowe; Colin L Masters
Journal:  Lancet Neurol       Date:  2013-03-08       Impact factor: 44.182

9.  Anatomic standardization: linear scaling and nonlinear warping of functional brain images.

Authors:  S Minoshima; R A Koeppe; K A Frey; D E Kuhl
Journal:  J Nucl Med       Date:  1994-09       Impact factor: 10.057

10.  A multi-center randomized proof-of-concept clinical trial applying [¹⁸F]FDG-PET for evaluation of metabolic therapy with rosiglitazone XR in mild to moderate Alzheimer's disease.

Authors:  Sofia Tzimopoulou; Vincent J Cunningham; Thomas E Nichols; Graham Searle; Nick P Bird; Prafull Mistry; Ian J Dixon; William A Hallett; Brandon Whitcher; Andrew P Brown; Marina Zvartau-Hind; Narinder Lotay; Robert Y K Lai; Mary Castiglia; Barbara Jeter; Julian C Matthews; Kewei Chen; Dan Bandy; Eric M Reiman; Michael Gold; Eugenii A Rabiner; Paul M Matthews
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

View more
  84 in total

1.  Cognitive signature of brain FDG PET based on deep learning: domain transfer from Alzheimer's disease to Parkinson's disease.

Authors:  Hongyoon Choi; Yu Kyeong Kim; Eun Jin Yoon; Jee-Young Lee; Dong Soo Lee
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-11-25       Impact factor: 9.236

Review 2.  FDG-PET Contributions to the Pathophysiology of Memory Impairment.

Authors:  Shailendra Segobin; Renaud La Joie; Ludivine Ritz; Hélène Beaunieux; Béatrice Desgranges; Gaël Chételat; Anne Lise Pitel; Francis Eustache
Journal:  Neuropsychol Rev       Date:  2015-08-30       Impact factor: 7.444

3.  Biomarker Localization, Analysis, Visualization, Extraction, and Registration (BLAzER) Methodology for Research and Clinical Brain PET Applications.

Authors:  Fabio Raman; Sameera Grandhi; Charles F Murchison; Richard E Kennedy; Susan Landau; Erik D Roberson; Jonathan McConathy
Journal:  J Alzheimers Dis       Date:  2019       Impact factor: 4.472

4.  A multilayer multimodal detection and prediction model based on explainable artificial intelligence for Alzheimer's disease.

Authors:  Shaker El-Sappagh; Jose M Alonso; S M Riazul Islam; Ahmad M Sultan; Kyung Sup Kwak
Journal:  Sci Rep       Date:  2021-01-29       Impact factor: 4.379

5.  Amyloid Load: A More Sensitive Biomarker for Amyloid Imaging.

Authors:  Alex Whittington; Roger N Gunn
Journal:  J Nucl Med       Date:  2018-09-06       Impact factor: 10.057

Review 6.  Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials.

Authors:  Michael W Weiner; Dallas P Veitch; Paul S Aisen; Laurel A Beckett; Nigel J Cairns; Robert C Green; Danielle Harvey; Clifford R Jack; William Jagust; John C Morris; Ronald C Petersen; Andrew J Saykin; Leslie M Shaw; Arthur W Toga; John Q Trojanowski
Journal:  Alzheimers Dement       Date:  2017-03-22       Impact factor: 21.566

7.  Relationships among Cortical Glutathione Levels, Brain Amyloidosis, and Memory in Healthy Older Adults Investigated In Vivo with 1H-MRS and Pittsburgh Compound-B PET.

Authors:  G C Chiang; X Mao; G Kang; E Chang; S Pandya; S Vallabhajosula; R Isaacson; L D Ravdin; D C Shungu
Journal:  AJNR Am J Neuroradiol       Date:  2017-03-24       Impact factor: 3.825

8.  The relationship between domain-specific subjective cognitive decline and Alzheimer's pathology in normal elderly adults.

Authors:  Sepideh Shokouhi; Alexander C Conley; Suzanne L Baker; Kimberly Albert; Hakmook Kang; Harry E Gwirtsman; Paul A Newhouse
Journal:  Neurobiol Aging       Date:  2019-05-23       Impact factor: 4.673

9.  Generation of Structural MR Images from Amyloid PET: Application to MR-Less Quantification.

Authors:  Hongyoon Choi; Dong Soo Lee
Journal:  J Nucl Med       Date:  2017-12-07       Impact factor: 10.057

10.  Near-infrared spectroscopy (NIRS) and vagus somatosensory evoked potentials (VSEP) in the early diagnosis of Alzheimer's disease: rationale, design, methods, and first baseline data of the Vogel study.

Authors:  Thomas Polak; Martin J Herrmann; Laura D Müller; Julia B M Zeller; Andrea Katzorke; Matthias Fischer; Fabian Spielmann; Erik Weinmann; Leif Hommers; Martin Lauer; Andreas J Fallgatter; Jürgen Deckert
Journal:  J Neural Transm (Vienna)       Date:  2017-09-01       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.